Recent Analysts’ Ratings Changes for Scholar Rock (SRRK)

A number of research firms have changed their ratings and price targets for Scholar Rock (NASDAQ: SRRK):

• 10/8/2026 – Scholar Rock had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc..
• 9/24/2026 – Scholar Rock had its price target raised by Truist Financial Corporation from $76.00 to $77.00. They now have a “buy” rating on the stock.
• 9/21/2026 – Scholar Rock had its “neutral” rating reaffirmed by Cantor Fitzgerald. They now have a $70.00 price target on the stock.
• 9/21/2026 – Scholar Rock had its price target raised by JPMorgan Chase & Co. from $63.00 to $70.00. They now have an “overweight” rating on the stock.
• 9/15/2026 – Scholar Rock had its “buy” rating reaffirmed by UBS Group AG.
• 9/15/2026 – Scholar Rock had its “outperform” rating reaffirmed by Evercore Inc. They now have a $72.00 price target on the stock.
• 9/15/2026 – Scholar Rock had its “outperform” rating reaffirmed by Wedbush. They now have a $64.00 price target on the stock.
• 9/15/2026 – Scholar Rock had its price target raised by Piper Sandler from $60.00 to $75.00. They now have an “overweight” rating on the stock.
• 9/15/2026 – Scholar Rock had its price target raised by HC Wainwright from $65.00 to $70.00. They now have a “buy” rating on the stock.
• 9/15/2026 – Scholar Rock was downgraded by Barclays PLC from “overweight” to “cautious”.
• 9/14/2026 – Scholar Rock had its “equal weight” rating reaffirmed by Barclays PLC. They now have a $58.00 price target on the stock, up from $55.00.
• 9/14/2026 – Scholar Rock had its price target raised by Jefferies Financial Group Inc. from $57.00 to $65.00. They now have a “buy” rating on the stock.
• 9/14/2026 – Scholar Rock had its “buy” rating reaffirmed by TD Cowen.
• 9/14/2026 – Scholar Rock had its price target raised by BMO Capital Markets from $76.00 to $84.00. They now have an “outperform” rating on the stock.
• 9/14/2026 – Scholar Rock had its “buy” rating reaffirmed by Truist Financial Corporation. They now have a $76.00 price target on the stock, up from $55.00.
• 9/14/2026 – Scholar Rock had its price target raised by Raymond James Financial, Inc. from $65.00 to $72.00. They now have a “strong-buy” rating on the stock.
• 9/14/2026 – Scholar Rock had its price target raised by Citigroup Inc. from $60.00 to $74.00. They now have a “buy” rating on the stock.
• 9/14/2026 – Scholar Rock was upgraded by Jefferies Financial Group Inc. to “strong-buy”.
• 9/14/2026 – Scholar Rock had its “outperform” rating reaffirmed by Wedbush. They now have a $64.00 price target on the stock.
• 9/10/2026 – Scholar Rock had its price target raised by BMO Capital Markets from $76.00 to $84.00. They now have an “outperform” rating on the stock.
• 9/8/2026 – Scholar Rock was downgraded by HC Wainwright from “buy” to “neutral”.
• 9/8/2026 – Scholar Rock had its “buy” rating reaffirmed by HC Wainwright. They now have a $65.00 price target on the stock.
• 8/21/2026 – Scholar Rock had its “outperform” rating reaffirmed by Wedbush. They now have a $64.00 price target on the stock.
• 8/13/2026 – Scholar Rock had its price target raised by JPMorgan Chase & Co. from $56.00 to $63.00. They now have an “overweight” rating on the stock.
• 8/10/2026 – Scholar Rock had its “buy” rating reaffirmed by HC Wainwright. They now have a $65.00 price target on the stock.
• 8/10/2026 – Scholar Rock had its “outperform” rating reaffirmed by Wedbush. They now have a $58.00 price target on the stock.

Scholar Rock Holding Corporation (NASDAQ: SRRK) is a clinical-stage biopharmaceutical company focused on developing medicines that selectively target the activation of growth factors. The company’s approach is designed to modulate biologic pathways in specific tissues while potentially limiting effects elsewhere in the body.

Scholar Rock’s lead product candidate is apitegromab, a monoclonal antibody designed to inhibit the activation of myostatin, a protein that negatively regulates muscle growth.